CCR8 and neoplasm: Experiments in immunocompetent mice, such as in the tumor-bearing humanized mouse model we used here or in genetically engineered mouse models of cancer, might determine whether depleting CCR8+ cells is safe and effective, and could be used to compare different approaches to control Treg suppression of tumor immunity.